GlobeNewswire Inc.··Immunocore Holdings PlcKIMMTRAK Doubles Five-Year Survival in Metastatic Uveal Melanoma
Immunocore's KIMMTRAK doubled five-year survival in metastatic uveal melanoma, achieving 16% vs. 8% control rate—longest T cell engager follow-up in solid tumors.
IMCRclinical trialimmunotherapy